197 related articles for article (PubMed ID: 18231720)
1. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess.
Ott SR; Allewelt M; Lorenz J; Reimnitz P; Lode H;
Infection; 2008 Feb; 36(1):23-30. PubMed ID: 18231720
[TBL] [Abstract][Full Text] [Related]
2. Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess.
Allewelt M; Schüler P; Bölcskei PL; Mauch H; Lode H;
Clin Microbiol Infect; 2004 Feb; 10(2):163-70. PubMed ID: 14759242
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and therapy of aspiration pneumonia].
Ott SR; Lode H
Dtsch Med Wochenschr; 2006 Mar; 131(12):624-8. PubMed ID: 16544240
[TBL] [Abstract][Full Text] [Related]
6. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Harkless L; Boghossian J; Pollak R; Caputo W; Dana A; Gray S; Wu D
Surg Infect (Larchmt); 2005; 6(1):27-40. PubMed ID: 15865549
[TBL] [Abstract][Full Text] [Related]
7. Ampicillin/sulbactam: current status in severe bacterial infections.
Rafailidis PI; Ioannidou EN; Falagas ME
Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
[TBL] [Abstract][Full Text] [Related]
8. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
Iannini PB
Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
[TBL] [Abstract][Full Text] [Related]
9. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae.
Tsukada H; Sakai K; Cho H; Kimura Y; Tetsuka T; Nakajima H; Ito K
J Infect Chemother; 2012 Oct; 18(5):715-21. PubMed ID: 22460828
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of azithromycin in aspiration pneumonia: a prospective observational study.
Marumo S; Teranishi T; Higami Y; Koshimo Y; Kiyokawa H; Kato M
BMC Infect Dis; 2014 Dec; 14():685. PubMed ID: 25491126
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin is efficacious for treatment of community-acquired lung abscesses in adults.
Polenakovik H; Burdette SD; Polenakovik S
Clin Infect Dis; 2005 Sep; 41(5):764-5. PubMed ID: 16080108
[No Abstract] [Full Text] [Related]
13. Vitamin K deficiency due to prolongation of antibiotic treatment and decrease in food intake in a catatonia patient.
Nomoto H; Hatta K; Usui C; Ito M; Kita Y; Arai H
Psychosomatics; 2011; 52(5):486-7. PubMed ID: 21907073
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
[TBL] [Abstract][Full Text] [Related]
15. Peritonsillar abscess: a comparison of outpatient i.m. clindamycin and inpatient i.v. ampicillin/sulbactam following needle aspiration.
Ozbek C; Aygenc E; Unsal E; Ozdem C
Ear Nose Throat J; 2005 Jun; 84(6):366-8. PubMed ID: 16075861
[TBL] [Abstract][Full Text] [Related]
16. 10 years' experience with the pneumococcal quinolone moxifloxacin.
Burkhardt O; Welte T
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):645-68. PubMed ID: 19681692
[TBL] [Abstract][Full Text] [Related]
17. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
[TBL] [Abstract][Full Text] [Related]
18. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli.
Harbarth S; Harris AD; Carmeli Y; Samore MH
Clin Infect Dis; 2001 Nov; 33(9):1462-8. PubMed ID: 11588690
[TBL] [Abstract][Full Text] [Related]
19. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
20. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.
Betrosian AP; Douzinas EE
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
